Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1377-1394

  Fabricius, Eva Maria ^a   Kruse Boitschenko, Ute ^a   Khoury, Reem ^a   Wildner, Gustav Paul ^b   Raguse, Jan Dirk ^a   Klein, Martin ^a   Hoffmeister, Bodo ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Section of Pathology   (Germany)

Author keywords

Basal cell carcinoma (BCC); Frozen sections; hTERT; Immunohistochemistry; p53; Prognosis; Telomerase; Tumor margin

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER RELAPSE; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STROMA; AGED; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CELL NUCLEUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FROZEN SECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SKIN NEOPLASMS; TELOMERASE;

EID: 73949087305     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000456     Document Type: Article

References (109)

1. English DR, Kricker A, Heenan PJ, Randell PL, Winter MG and Armstrong BK: Incidence of non-melanocytic skin cancer in Geraldton, Western Australia. Int J Cancer 73: 629-633, 1997.
2. Harris RB, Griffith K and Moon TE: Trends in the incidence of nonmelanoma skin cancers in Southeastern Arizona, 1985-1996. J Am Acad Dermatol 45: 528-536, 2001.
3. Koh D, Wang H, Lee J, Chia KS, Lee HP and Goh CL: Basalcell carcinoma, squamous-cell carcinoma and melanoma of the skin: analysis of the Singapore cancer registry data 1968-97. Br J Dermatol 148: 1161-1166, 2003.
4. Katalinic A, Kunze U and Schäfer T: Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149: 1200-1206, 2003.
5. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E and Kerl H: Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 157: 47-51, 2007.
6. Lear W, Dahlke E and Murray CA: Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg 11: 19-30, 2007.
7. Epstein EH: Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 8: 743-754, 2008.
8. Kyrgidis A, Tzellos TG, Vahtsevanos K and Triaridis S: New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res (In press).
9. Leiter U and Garbe C: Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 624: 89-103, 2008.
10. McGuire JF, Ge NN and Dyson S: Nonmelanoma skin cancer of the head and neck. I. Histopathology and clinical behavior. Am J Otolaryngol 30: 121-133, 2009.
11. Quinn AG: Ultraviolet radiation and skin carcinogenesis. Br J Hosp Med 58: 261-264, 1997.
12. English DR, Armstrong BK, Kricker A and Fleming C: Sunlight and cancer. Cancer Causes Control 8: 271-283, 1997.
13. Ouhtit A and Ananthaswamy HN: A model for UV-induction of skin cancer. J Biomed Biotechnol 1: 5-6, 2001.
14. Seidl H, Kreimer-Erlacher H, Bäck B, Soyer HP, Höfler G, Kerl H and Wolf P: Ultraviolet exposure as the main initiator of p53 mutations in basal-cell carcinomas from psorialen and ultraviolet A-treated patients with psoriasis. J Invest Dermatol 117: 365-370, 2001.
15. Hussein MR: Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 32: 191-205, 2005.
16. Greinert R: Skin cancer: new markers for better prevention. Pathobiology 76: 64-81, 2009.
17. Sander CS, Hamm F, Elsner P and Thiele JJ: Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 148: 913-922, 2003.
18. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin A J and Ponten J: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous-cell carcinoma. Proc Natl Acad Sci USA 88: 10124-10128, 1991.
19. Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H and English DR: UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal-cell carcinoma. J Natl Cancer Inst 90: 523-531, 1998.
20. Liang SB, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Chen BK and Sonobe H: Sun-exposure- and aging-dependent p53 protein accumulation results in growth advantage for tumour cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 434: 193-199, 1999.
21. Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, Lippman SM, Kripke ML and Ananthaswamy HN: P53 mutations in human aggressive and nonaggressive basal and squamous-cell carcinomas. Clin Cancer Res 9: 228-234, 2003.
22. Marrot L and Meunier JR: Skin DNA photodamage and its biological consequences. J Am Acad Dermatol 58: S139-S148, 2008.
23. Ueda M, Ouhtit A, Bito T, Nakazawa K, Lübbe J, Ichihashi M, Yamasaki H and Nakazawa H: Evidence for UV-associated activation of telomerase in human skin. Cancer Res 57: 370-374, 1997.
24. Fabricius EM, Bezeluk A, Kruse-Boitschenko U, Wildner GP and Klein M: Clinical significance of telomerase activity in basal cell carcinomas and in tumour-free surgical margins. Int J Oncol 23: 1389-1399, 2003.
25. Park HR, Min SK, Cho HD, Kim KH, Shin HS and Park YE: Expression profiles of p63, p53, surviving, and hTERT in skin tumors. J Cutan Pathol 31: 544-549, 2004.
26. Fabricius E-M: Molecular mechanisms of basal cell and squamous cell carcinomas. In: The Role of Telomerase for Cancerogenesis of Basal Cell and Squamous Cell Carcinomas. Reichrath J (ed). Landes Bioscience and Springer Science + Bisness Media Inc., New York, pp115-133, 2006.
27. Burnworth B, Arendt S, Muffler S, Steinkraus V, Brocker EB, Birek C, Hartschuh W, Jauch A and Boukamp P: The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur J Cell Biol 86: 763-780, 2007.
28. Slaughter D, Southwick H and Smejkal W: 'Field cancerization' in oral stratified squamous epithelium. Cancer 6: 963-968, 1953.
29. Mertens F, Heim S, Mandahl N, Johansson B, Mertens O, Persson B, Salemark L, Wennerberg J, Jonsson N and Mitelman F: Cytogenetic analysis of 33 basal cell carcinomas. Cancer Res 51: 954-957, 1991.
30. Kanjilal S, Strom SS, Clayman GL, Weber RS, El-Naggar AK, Kapur V, Cummings KK, Hill LA, Spitz MR, Kripke ML and Ananthaswamy HN: p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 55: 3604-3609, 1995.
31. Stern R, Bolshakov S, Nataraj A and Ananthaswamy H: p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet A-treated patients: evidence for heterogeneity and field cancerization. J Investig Dermatol 119: 522-526, 2002.
32. Sidoroff A: Photodynamische Therapie bei epithelialen Hauttumoren. Evidenzbasierte Datenlage. Hautarzt 58: 577-584, 2007.
33. Ponten F, Berg C, Ahmadian A, Ren Z, Nister M, Lundeberg J, Uhlen M and Ponten J: Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 15: 1059-1067, 1997.
34. Brennan P, Umar T, Bowden J, Hobkirk A, Spedding A, Conroy B, Zaki G and Macpherson D: Nitric oxide synthase expression is downregulated in basal cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 38: 633-636, 2000.
35. Demirkan N, Colakoglu N and Duzcan E: Value of p53 protein in biological behavior of basal cell carcinoma and in normal epithelia adjacent to carcinomas. Pathol Oncol Res 6: 272-274, 2000.
36. Aiad HA and Hanout HM: Immunohistochemical Expression of CD10 in Cutaneous Basal and Squamous Cell Carcinomas. J Egypt Natl Cancer Inst 19: 195-201, 2007.
37. Kim N, Piatyszek M, Prowse K, Harley C, West M, Ho P, Coviello G, Wright W, Weinrich S and Shay J: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
38. Taylor R, Ramirez R, Ogoshi M, Chaffins M, Piatyszek M and Shay J: Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 106: 759-765, 1996.
39. Shay J and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
40. Parris C, Jezzard S, Silver A, MacKie R, McGregor J and Newbold R: Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer 79: 47-53, 1999.
41. Wu A, Ichihashi M and Ueda M: Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer 86: 2038-2044, 1999.
42. Dhaene K, van Marck E and Parwaresch R: Telomeres, telomerase and cancer: an up-date. Virchows Arch 437: 1-16, 2000.
43. Ueda M: Telomerase in cutaneous carcinogenesis. J Dermatol Sci 23: S37-S40, 2000.
44. Kim B-C, Ryoo Y-W and Lee K-S: Telomerase activity in squamous cell carcinoma and basal cell carcinoma. Korean J Investigativ Dermatol 7: 184-187, 2000.
45. Chen Z, Smith K, Skelton HG 3rd, Barrett T, Greenway HJ and Lo S: Telomerase activity in Kaposi's sarcoma, squamous cell carcinoma, and basal cell carcinoma. Exp Biol Med (Maywood) 226: 753-757, 2001.
46. Dicker T, Siller G and Saunders N: Molecular and cellular biology of basal cell carcinoma. Australas J Dermatol 43: 241-246, 2002.
47. Hu S, Chan HL, Chen MC and Pang JH: Telomerase expression in benign and malignant skin neoplasms: comparison of three major subunits. J Formos Med Assoc 101: 593-597, 2002.
48. Boldrini L, Loggini B, Gisfredi S, Zucconi Y, Di Quirico D, Biondi R, Cervadoro G, Barachini P, Basolo F, Pingitore R and Fontanini G: Evaluation of telomerase in non-melanoma skin cancer. Int J Mol Med 11: 607-611, 2003.
49. Bezeluk A: Bestimmung der Telomeraseaktivität in Basalzellkarzinom-Geweben und in Basalzellkarzinom-freien Tumorrandgeweben des Kopf-Hals-Bereichs in der PCR unter dem Aspekt der prognostischen Aussage. Dissertation der medizinischen Fakultät der Humboldt-Universität Berlin. pp1-133, 2005.
50. Saleh S, Lam AK, Buettner GP, Glasby M, Raasch B and Ho YH: Telomerase activity of basal cell carcinoma in patients living in North Queensland, Australia. Hum Pathol 38: 1023-1029, 2007.
51. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ and De Vivo I: A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 129: 415-421, 2009.
52. Fabricius E-M, Kruse-Boitschenko U, Khoury R, Wildner G-P, Raguse J-D and Klein M: Immunohistochemical determination of the appropriate anti-hTERT antibodies for in situ detection of telomerase activity in frozen sections of head and neck squamous cell carcinomas and tumor margin tissues. Int J Oncol 34: 1257-1279, 2009.
53. Soyer HP: Trichoblastic carcinoma. In: Neoplasms with follicular differentiation, Chapter 23. Ackerman AB, Reddy VB and Soyer HP (eds). Ardor Scribendi, USA, pp625-1007, 2001.
54. Rippey JJ: Why classify basal cell carcinomas? Histopathology 32: 393-398, 1998.
55. Wittekind Ch, Meyer HJ and Bootz F (eds): TNM Klassifikation maligner Tumoren. UICC International Union Against Cancer 6. Aufl. Korr. Nachdruck. Kopf- und Halstumoren, pp19-52, 2005.
56. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H and Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229, 1984.
57. Fabricius E-M, Langford A, Bier J, Hell B, Wildner G-P and Blümcke S: Immunohistochemical characterization of E48 and CD44-v6 expression in head and neck carcinomas. Cancer J 10: 325-330, 1997.
58. Fabricius E-M, Guschmann M, Wildner G, Langford A, Hell B and Bier J: Divergent immunohistochemical E48 and CD44-v6 antigen expression patterns between lymph node metastases and primary squamous cell carcinomas in the head and neck region. Cancer J 11: 325-330, 1998.
59. Fabricius E-M, Guschmann M, Langford A, Hell B and Bier J: Immunhistochemical assessment of the tumour-associated epitopes CD44v6 and E48 in tumour-free lymph nodes from patients with squamous cell carcinoma in the head-neck region. Anal Cell Pathol 20: 115-129, 2000.
60. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek M-A, Shay J-W, Ishioka S and Yamakido M: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711-3715, 1995.
61. Yamada O, Motoji T and Mizoguchi H: Up-regulation of telomerase activity in human lymphocytes. Biochim Biophys Acta 1314: 260-266, 1996.
62. Fabricius E-M, Gurr U and Wildner G-P: Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head-and-neck. Anal Cell Pathol 24: 25-39, 2002.
63. Gurr U: Der Nachweis der Telomeraseaktivierung in Tumorgeweben und dem Tumor benachbarten Geweben von Plattenepithelkarzinomen im Kopf-Hals-Bereich. Dissertation der medizinischen Fakultät der Humboldt-Universität Berlin. pp1-106, 2003.
64. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ and Segal-Bendirdjian E: Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 119: 2797-2806, 2006.
65. Remmele W, Hildebrand U, Hienz HA, Klein P-J, Vierbuchen M, Behnken LJ, Heicke B and Scheidt E: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 409: 127-147, 1986.
66. Remmele W und Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRE) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammagewebe. Pathologie 8: 138-140, 1987.
67. Diehl JM und Staufenbiel T: Statistik mit SPSS für Windows Version 15. Verlag Dietmar Klotz, Eschborn, pp720, 2007.
68. Wernicke KD: Medizinische Biometrie - Planung und Auswertung medizinischer Studien - Skriptum zur Lehrveranstaltung 'Biomathematik/Biometrie' für Humanmediziner. Institut für Medizinische Biometrie, Universitätsklinikum Charité, Berlin, p126, 2003.
69. Sachs L: Angewandte Statistik - Anwendung statistischer Methoden. 11. Auflage Springer Verlag, Berlin, p889, 2004.
70. Brasanac D, Boricic I, Todorovic V and Tomanovic N: Primary cutaneous carcinosarcoma: case report with expanded immunohistochemical analysis. Int J Dermatol 47: 496-501, 2008.
71. Perrem K, Lynch A, Al Nooh F, Leader M and Kay E: The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol 39: 1034-1041, 2008.
72. Guttman-Yassky E, Bergman R, Manov L, Sprecher E, Shaefer Y and Kerner H: Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. J Cutan Pathol 29: 341-346, 2002.
73. Yan P, Benhattar J, Seelentag W, Stehle JC and Bosman FT: Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 121: 391-397, 2004.
74. Hiyama E, Hiyama K, YokoyamaT and Shay JW: Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3: 17-26, 2001.
75. Poremba C, Hero B, Heine B, Scheel C, Schaefer K-L, Christiansen H, Berthold F, Kneif S, Stein H, Juergens H, Boecker W and Dockhorn-Dworniczak B: Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol 35: 651-655, 2000.
76. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama J, Berthold F, Juergens H, Boecker W and Dockhorn-Dworniczak B: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18: 2582-2592, 2000.
77. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer K-L, Braun Y, Schuck A, Lanvers C, Bànkfalvi À, Kneif S, Torhorst J, Zuber M, Köchli OR, Mross F, Dieterich H, Sauter G, Stein H, Fogt F and Boecker W: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 198: 181-189, 2002.
78. Taylor CR, Shi SR, Chen C, Young L, Yang C and Cote RJ: Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem 71: 263-270, 1996.
79. Kleinschmidt K: Inaugural-Dissertation zur Erlangung des Grades einer Doktorin der Veterinärmedizin (Dr. med. vet.) durch die Tierärztliche Hochschule Hannover: Untersuchung von Endostatin freisetzenden Stammzellimplantaten zur Behandlung des Glioblastoms im Rattenmodell, pp1-207, 2006.
80. Yang Y, Chen Y, Zhang C, Huang H and Weissman SM: Nucleolar localization of hTERT protein is associated with telomerase function. Exper Cell Res 277: 201-209, 2002.
81. Ogoshi M, Le T, Shay J and Taylor R: In situ hybridization analysis of the expression of human telomerase RNA in normal and pathologic conditions of the skin. J Invest Dermatol 110: 818-823, 1998.
82. Luzar B, Poljak M and Gale N: Telomerase catalytic subunit in laryngeal carcinogenesis - an immunohistochemical study. Mod Pathol 18: 406-411, 2005.
83. Volpi A, Bravaccini S, Medri L, Cerasoli S, Gaudio M and Amadori D: Usefulness of immunological detection of the human telomerase reverse transcriptase. Cell Oncol 27: 347-353, 2005.
84. Broccoli D, Young JW and de Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 92: 9082-9086, 1995.
85. Bodnar AG, Kim NW, Effros RB and Chiu CP: Mechanism of telomerase induction during T cell activation. Exp Cell Res 228: 58-64, 1996.
86. Shay JW and Wright WE: Telomerase activity in human cancer. Curr Opin Oncol 8: 66-71, 1996.
87. Kaur P, Mulvaney M and Carlson JA: Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 28: 293-307, 2006.
88. Lantuejoul S, Salon C, Soria J-C and Brambilla E: Mini review: telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 120: 1835-1841, 2007.
89. Lam AK, Ong K and Ho YH: hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorectal Dis 23: 587-594, 2008.
90. Cassaro M, Rugge M, Tieppo C, Giacomelli L, Velo D, Nitti D and Farinati F: Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. J Clin Pathol 60: 615-621, 2007.
91. Olsen SH, Su LD, Thomas D and Fullen DR: Telomerase expression in sebaceous lesions of the skin. J Cutan Pathol 34: 386-391, 2007.
92. Zendehrokh N, Rehnberg J and Dejmek A: Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions. Acta Cytol 51: 886-892, 2007.
93. Yang CH, Hung WC, Wang SL, Kang WY, Chen WT, Huang YC, Su YC and Chai CY: Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma. APMIS 116: 309-316, 2008.
94. Forsyth R, De Boeck G, Bekaert S, De Meyer T, Taminiau A, Uyttendaele D, Roels H, Praet M and Hogendoorn P: Telomere biology in giant cell tumour of bone. J Pathol 214: 555-563, 2008.
95. Tabori U, Wong V, Ma J, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D and Hawkins C: Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 99: 1129-1135, 2008.
96. Tantbirojn P, Triratanachat S, Trivijitsilp P and Niruthisard S: Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. J Med Assoc Thai 92: 308-314, 2009.
97. Zachos I, Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Papatsoris AG, Podimatas T, Papachristodoulou A, Chrisofos M, Deliveliotis C and Papavassiliou AG: Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol 135: 1169-1175, 2009.
98. Mitsuishi T, Nakatake M, Kaneko T, Ohara K, Kato T, Iida K, Iwabu Y, Tokunaga K, Sata T, Kawana S and Yamada O: Evaluation of telomerase activity in non-genital Bowen's disease. J Eur Acad Dermatol Venereol 23: 668-672, 2009.
99. Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG and on behalf of the Children's Cancer and Leukaemia Group Biological Studies Committee: Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 10: 675-689, 2008.
100. Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, Hayashi N, Hahn WC and Murakami S: Nucleolin interacts with telomerase. J Biol Chem 279: 51508-51515, 2004.
101. Hiyama E and Hiyama K: Telomerase as tumor marker. Cancer Lett 194: 221-233, 2003.
102. Hiyama E and Hiyama K: Telomerase detection in the diagnosis and prognosis of cancer. Cytotechnology 45: 61-74, 2004.
103. Miyazu YM, Miyazawa T, Hiyama K, Kurimoto N, Iwamoto Y, Matsuura H, Kanoh K, Kohno N, Nishiyama M and Hiyama E: Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. Cancer Res 65: 9623-9627, 2005.
104. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Sueda T and Hiyama E: Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery 143: 113-125, 2008.
105. Tao Z, Chen S, Wu Z, Xiao B, Liu J and Hou W: Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA. J Laryngol Otol 119: 92-96, 2005.
106. Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K and Georgoulias V: A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 70: 306-314, 2006.
107. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V and Mavroudis D: Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25: 2727-2734, 2007.
108. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA and Gaudernack G: Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55: 1553-1564, 2006.
109. Wenandy L, Sørensen RB, Sengeløv L, Svane IM, Thor Straten P and Andersen MH: The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 14: 4-7, 2008.